COPENHAGEN (Reuters) – Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous expectation to file towards end-2025.
“In order to secure supply chain readiness, Novo Nordisk now expects to file for the first regulatory approval of CagriSema during the first quarter of 2026,” The Danish company said in its full-year.
(Reporting by Stine Jacobsen)
Source link : https://www.medscape.com/s/viewarticle/novo-nordisk-seek-regulatory-approval-cagrisema-obesity-drug-2025a10002th?src=rss
Author :
Publish date : 2025-02-05 07:41:37
Copyright for syndicated content belongs to the linked Source.